The U.S. Department of Justice has sued New York-Presbyterian Hospital, alleging that its contracts with insurers suppressed competition and restricted the availability of lower-cost health plans in New York.
The case, brought by the U.S. Department of Justice Antitrust Division and federal prosecutors in New York, puts a sharp legal focus on when contract design, rather than pricing itself, becomes an unlawful restraint of trade under the Sherman Act.
Alleged Contract Restrictions Limiting Competition
According to the DOJ, New York-Presbyterian Hospital, described as the largest hospital system in New York City, imposed contractual restrictions on insurers and other payors that limited how health plans could be structured and priced.
The complaint alleges that insurers were prevented from offering “budget-conscious” plans that either excluded New York-Presbyterian or placed it outside the most favourable pricing tier.
It also claims that payors were restricted from offering lower copays to steer patients toward competing hospitals.
In addition, the government alleges that insurers were required to contract with the system on an “all-or-nothing” basis, preventing selective inclusion of individual hospitals.
According to the DOJ, these restrictions insulated New York-Presbyterian from price competition, limited rivals’ ability to compete on cost and value, and reduced consumer choice in the New York healthcare market.
How the DOJ Will Argue the Case
The case turns on how courts assess contractual restraints under Section 1 of the Sherman Act — specifically, whether the alleged restrictions unreasonably limit competition.
In practice, courts examine several factors, including:
- Market power — whether a provider has sufficient influence that insurers cannot realistically exclude it
- Competitive effects — whether the conduct limits rivals’ ability to compete on price or value
- Consumer impact — whether the restrictions lead to higher costs or reduced choice
According to the DOJ’s complaint, New York-Presbyterian Hospital’s scale and position in the New York City market meant insurers could not viably offer plans without including it.
The government alleges that contractual mechanisms — including “all-or-nothing” provisions and restrictions on plan design — were used to avoid competitive pressure rather than compete on price.
The DOJ contends that this conduct violates Section 1 of the Sherman Act, which prohibits agreements that unreasonably restrain trade.
In announcing the case, Attorney General Pamela Bondi said the alleged practices contributed to higher healthcare costs for millions of New Yorkers.
Acting Assistant Attorney General Omeed A. Assefi stated that the hospital system used its market position to impede competition and prevent the development of lower-cost health plans.
U.S. Attorney Jay Clayton for the Southern District of New York added that the office would continue to work with the Antitrust Division to address practices contributing to rising healthcare costs.
At its core, the case focuses not on pricing itself, but on whether contract structure can be used to suppress competition.
Legal Exposure and Penalties
The case is a civil antitrust action alleging violations of Section 1 of the Sherman Act.
The DOJ is seeking injunctive relief to prevent New York-Presbyterian from continuing to impose the challenged contractual restrictions, and to prohibit the use of similar provisions that could produce comparable competitive effects.
No criminal charges have been filed. The DOJ release does not specify financial penalties, damages, or restitution.
The case is pending before the U.S. District Court for the Southern District of New York. No timetable for further proceedings is specified in the DOJ release.
Antitrust Risk: What This Means for Businesses and Compliance Teams
At its core, the case signals a shift in antitrust risk: liability may arise not from pricing itself, but from how contracts shape competition.
For general counsel and senior executives, the implications are immediate:
Contract design can create exposure
Clauses governing network inclusion, tiering, or plan structure may come under scrutiny where they limit insurers’ ability to offer lower-cost or alternative options.
“All-or-nothing” provisions carry heightened risk
The allegations focus on arrangements requiring full-system inclusion. These structures may raise concerns where they prevent selective contracting or restrict competition between providers.
Market position increases scrutiny
Organisations with strong regional presence may face greater regulatory attention where contractual terms influence pricing dynamics across a market.
Indirect pricing controls are under focus
The case centres on copay restrictions and plan design rather than explicit price-setting, reinforcing that antitrust exposure extends to mechanisms that shape pricing outcomes indirectly.
Employers and insurers sit within the risk chain
Businesses offering health benefits, and insurers structuring those plans, may face indirect exposure where contractual arrangements limit cost-saving options or restrict competition.
What This Signals for Healthcare Antitrust Enforcement
The DOJ states that this is the second case it has brought this year focused on competition in healthcare markets, particularly where contractual practices may affect affordability.
In this case, the focus is on how contract terms, including network inclusion requirements and restrictions on plan design — may limit insurers’ ability to offer lower-cost options.
The emphasis on these mechanisms suggests continued scrutiny of large healthcare systems whose commercial agreements shape pricing dynamics without directly setting prices.
While the release does not outline a broader enforcement programme, it reinforces that non-merger conduct — particularly contract-based restrictions — remains an active area of antitrust enforcement.
What Happens Next
The case will proceed in the U.S. District Court for the Southern District of New York, where the government will seek to block the contractual practices identified in the complaint.
At this stage, the DOJ is pursuing injunctive relief rather than financial penalties, and no timetable for further proceedings has been specified in the release.
The outcome will determine whether the challenged contract provisions can continue to be used in the New York healthcare market.
Case Details
- Court: U.S. District Court for the Southern District of New York
- District: Southern District of New York
- Case posture: Civil antitrust lawsuit (filed)
- Lead agencies: U.S. Department of Justice Antitrust Division; U.S. Attorney’s Office for the Southern District of New York
- DOJ components: Antitrust Division; U.S. Attorney’s Office (SDNY)
- Date of announcement: March 26, 2026
People Also Ask
1. What makes a hospital contract illegal under antitrust law?
A contract may be unlawful if it restricts competition, limits consumer choice, or prevents lower-cost alternatives from being offered.
2. What are “all-or-nothing” clauses in healthcare contracts?
They are provisions requiring insurers to include all facilities within a hospital system rather than selecting individual providers.
3. Why is the DOJ focusing on healthcare contracts?
Because certain contractual practices may limit competition and contribute to higher healthcare costs for consumers.